Search

Your search keyword '"M.J. Jacobsen"' showing total 2 results
Start Over Author "M.J. Jacobsen"
2 results on '"M.J. Jacobsen"'

1. Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications

Author

AC. Kiel Rasmussen, T.M. Hulen, D.L. Petersen, M.J. Jacobsen, M.J. Mikkelsen, Ö. Met, M. Donia, C.A. Chamberlain, and P. Mouritzen

Subjects
Xdrop, cancer immunotherapy, single-cell analysis, cell therapy, microfluidics, cell characterization, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Cellular effector function assays traditionally rely on bulk cell populations that mask complex heterogeneity and rare subpopulations. The Xdrop® droplet technology facilitates high-throughput compartmentalization of viable single cells or single-cell pairs in double-emulsion droplets, enabling the study of single cells or cell–cell interactions at an individual level. Effector cell molecule secretion and target cell killing can be evaluated independently or in combination. Compatibility with a wide range of commercial assay reagents allows for single-cell level readouts using common laboratory techniques such as flow cytometry or microscopy. Moreover, individual cells of interest can be viably isolated for further investigation or expansion. Here we demonstrate the application of the double-emulsion droplet technology with a range of cell types commonly utilized for adoptive cell therapy of cancer: natural killer cells, blood-derived T cells, tumor-infiltrating lymphocytes, and chimeric antigen receptor T cells. Single-cell compartmentalization offers unparalleled resolution, serving as a valuable tool for advancing the development and understanding of cellular therapy products.

Published
2024
Full Text
View/download PDF

2. Experimental Vaccination of Pigs with an Actinobacillus pleuropneumoniae Serotype 5b Capsular Polysaccharide-Tetanus Toxoid Conjugate

Author

Jens Nielsen, M.J. Jacobsen, and Lars Ole Andresen

Subjects
Male, Serotype, Swine, medicine.medical_treatment, Group A, Article, Group B, Microbiology, Actinobacillus Infections, Antigen, Tetanus Toxoid, Animals, Medicine, Swine Diseases, Vaccines, Conjugate, General Veterinary, business.industry, Tetanus, Actinobacillus pleuropneumoniae, Polysaccharides, Bacterial, Vaccination, Toxoid, General Medicine, medicine.disease, Bacterial Vaccines, Female, business, Adjuvant
Abstract

The protective efficacy of an Actinobacillus pleuropneumoniae serotype 5b capsular polysaccharide-tetanus toxoid conjugate (Ap5bCP-TT) against homologous challenge of pigs was investigated. Four pigs were non-vaccinated controls (group A), 4 pigs were injected with adjuvant without antigen (group B) and 8 pigs were vaccinated with Ap5bCP-TT and adjuvant (group C). Pigs vaccinated with Ap5bCP-TT developed antibody responses to the capsular polysaccharide from A. pleuropneumoniae serotype 5b (Ap5bCP). After challenge, all pigs in groups A and B had severe clinical signs of disease and were euthanized. In group C, 3 out of 8 pigs showed severe symptoms and were euthanized. Five pigs in group C survived throughout the study. The post challenge observation period was 72 h. All pigs were subject to necropsy and results from gross pathological findings and microbiological examination are described. Pigs vaccinated with Ap5bCP-TT had statistically significant reduced values of the mass ratio of affected to unaffected lung tissue compared to pigs in groups A and B (p = 0.01 and p = 0.007, respectively). The results showed that Ap5bCP-TT-vaccination had considerable protective efficacy against lethality and pulmonary lesions caused by experimental infection with A. pleuropneumoniae serotype 5b.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results